Sex steroids, insulin sensitivity and sympathetic nerve activity in relation to affective symptoms in women with polycystic ovary syndrome

Psychoneuroendocrinology

Volumn 36, Issue 10, 2011, Pages 1470-1479

  Jedel, Elizabeth ^a   Gustafson, Deborah ^b,c   Waern, Margda ^b   Sverrisdottir, Yrsa Bergmann ^b   Landén, Mikael ^b   Janson, Per Olof ^d   Labrie, Fernand ^e   Ohlsson, Claes ^b   Stener Victorin, Elisabet ^b,f  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c SUNY DOWNSTATE MEDICAL CENTER   (United States)

^d SAHLGRENSKA ACADEMY AT UNIVERSITY OF GOTHENBURG   (Sweden)

^e LAVAL UNIVERSITY   (Canada)

^f HEILONGJIANG UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Anxiety; Depression; Estrogens; PCOS; Sex hormone binding globulin; Sympathetic nerve activity; Testosterone

Indexed keywords

ANDROGEN; ANDROSTANE 3ALPHA 17BETA DIOL 3 GLUCURONIDE; ESTROGEN; SEX HORMONE; TESTOSTERONE; UNCLASSIFIED DRUG;

ADULT; ANDROGEN BLOOD LEVEL; ANXIETY; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEPRESSION; DISEASE ASSOCIATION; EMOTIONAL DISORDER; ESTROGEN BLOOD LEVEL; FEMALE; HUMAN; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MONTGOMERY ASBERG DEPRESSION RATING SCALE; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; RISK ASSESSMENT; SELF REPORT; SYMPATHETIC FUNCTION; SYMPATHETIC NERVE ACTIVITY; TESTOSTERONE BLOOD LEVEL;

ADOLESCENT; ADULT; AFFECTIVE SYMPTOMS; ANXIETY; CROSS-SECTIONAL STUDIES; DEPRESSION; FEMALE; GONADAL STEROID HORMONES; HUMANS; IMMUNOASSAY; INSULIN RESISTANCE; MASS SPECTROMETRY; POLYCYSTIC OVARY SYNDROME; PSYCHOMETRICS; SYMPATHETIC NERVOUS SYSTEM; YOUNG ADULT;

EID: 80052178719     PISSN: 03064530     EISSN: 18733360     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2011.04.001     Document Type: Article

References (39)

1. Adali E., Yildizhan R., Kurdoglu M., Kolusari A., Edirne T., Sahin H.G., Yildizhan B., Kamaci M. The relationship between clinico-biochemical characteristics and psychiatric distress in young women with polycystic ovary syndrome. J. Int. Med. Res. 2008, 36:1188-1196.
2. Asberg M., Montgomery S.A., Perris C., Schalling D., Sedvall G. A comprehensive psychopathological rating scale. Acta Psychiatr. Scand. Suppl. 1978, 5-27.
3. Deeks A.A., Gibson-Helm M.E., Teede H.J. Anxiety and depression in polycystic ovary syndrome: a comprehensive investigation. Fertil. Steril. 2010, 93:2421-2423.
4. DeFronzo R.A., Tobin J.D., Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am. J. Physiol. 1979, 237(September):E214-E223.
5. Ferriman D., Gallwey J.D. Clinical assessment of body hair growth in women. J. Clin. Endocrinol. Metab. 1961, 21:1440-1447.
6. Glintborg D., Andersen M. An update on the pathogenesis, inflammation, and metabolism in hirsutism and polycystic ovary syndrome. Gynecol. Endocrinol. 2010, 26:281-296.
7. Guapo V.G., Graeff F.G., Zani A.C., Labate C.M., dos Reis R.M., Del-Ben C.M. Effects of sex hormonal levels and phases of the menstrual cycle in the processing of emotional faces. Psychoneuroendocrinology 2009, 34:1087-1094.
8. Harvey A.T., Hitchcock C.L., Prior J.C. Ovulation disturbances and mood across the menstrual cycles of healthy women. J. Psychosom. Obstet. Gynaecol. 2009, 30:207-214.
9. Hatch R., Rosenfield R.L., Kim M.H., Tredway D. Hirsutism: implications, etiology, and management. Am. J. Obstet. Gynecol. 1981, 140:815-830.
10. Hollinrake E., Abreu A., Maifeld M., Van Voorhis B.J., Dokras A. Increased risk of depressive disorders in women with polycystic ovary syndrome. Fertil. Steril. 2007, 87:1369-1376.
11. Holsen L.M., Spaeth S.B., Lee J.H., Ogden L.A., Klibanski A., Whitfield-Gabrieli S., Goldstein J.M. Stress response circuitry hypoactivation related to hormonal dysfunction in women with major depression. J. Affect. Disord. 2010, [Epub ahead of print].
12. Jedel E., Waern M., Gustafson D., Landen M., Eriksson E., Holm G., Nilsson L., Lind A.K., Janson P.O., Stener-Victorin E. Anxiety and depression symptoms in women with polycystic ovary syndrome compared with controls matched for body mass index. Hum. Reprod. 2010, 25:450-456.
13. Lambert E., Dawood T., Schlaich M., Straznicky N., Esler M., Lambert G. Single-unit sympathetic discharge pattern in pathological conditions associated with elevated cardiovascular risk. Clin. Exp. Pharmacol. Physiol. 2008, 35:503-507.
14. Lambert E., Dawood T., Straznicky N., Sari C., Schlaich M., Esler M., Lambert G. Association between the sympathetic firing pattern and anxiety level in patients with the metabolic syndrome and elevated blood pressure. J. Hypertens. 2010, 28:543-550.
15. Lambert E., Hotchkin E., Alvarenga M., Pier C., Richards J., Barton D., Dawood T., Esler M., Lambert G. Single-unit analysis of sympathetic nervous discharges in patients with panic disorder. J. Physiol. 2006, 570:637-643.
16. Lu X.Y., Kim C.S., Frazer A., Zhang W. Leptin: a potential novel antidepressant. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:1593-1598.
17. Manneras-Holm L., Leonhardt H., Kullberg J., Jennische E., Oden A., Holm G., Hellstrom M., Lonn L., Olivecrona G., Stener-Victorin E., Lonn M. Adipose tissue has aberrant morphology and function in PCOS: enlarged adipocytes and low serum adiponectin, but not circulating sex steroids, are strongly associated with insulin resistance. J. Clin. Endocrinol. Metab. 2011, 96:E304-E311.
18. Mansson M., Holte J., Landin-Wilhelmsen K., Dahlgren E., Johansson A., Landen M. Women with polycystic ovary syndrome are often depressed or anxious-a case control study. Psychoneuroendocrinology 2008, 33:1132-1138.
19. Miller K.K., Perlis R.H., Papakostas G.I., Mischoulon D., Losifescu D.V., Brick D.J., Fava M. Low-dose transdermal testosterone augmentation therapy improves depression severity in women. CNS Spectr. 2009, 14:688-694.
20. Montgomery S.A., Asberg M. A new depression scale designed to be sensitive to change. Br. J. Psychiatry 1979, 134:382-389.
21. Moran L., Gibson-Helm M., Teede H., Deeks A. Polycystic ovary syndrome: a biopsychosocial understanding in young women to improve knowledge and treatment options. J. Psychosom. Obstet. Gynaecol. 2010, 31:24-31.
22. Morsink L.F., Vogelzangs N., Nicklas B.J., Beekman A.T., Satterfield S., Rubin S.M., Yaffe K., Simonsick E., Newman A.B., Kritchevsky S.B., Penninx B.W. Associations between sex steroid hormone levels and depressive symptoms in elderly men and women: results from the Health ABC study. Psychoneuroendocrinology 2007, 32:874-883.
23. Pusalkar M., Meherji P., Gokral J., Savardekar L., Chinnaraj S., Maitra A. Obesity and polycystic ovary syndrome: association with androgens, leptin and its genotypes. Gynecol. Endocrinol. 2010, 26:874-882.
24. Rofey D.L., Szigethy E.M., Noll R.B., Dahl R.E., Lobst E., Arslanian S.A. Cognitive-behavioral therapy for physical and emotional disturbances in adolescents with polycystic ovary syndrome: a pilot study. J. Pediatr. Psychol. 2009, 34:156-163.
25. Santoro N., Torrens J., Crawford S., Allsworth J.E., Finkelstein J.S., Gold E.B., Korenman S., Lasley W.L., Luborsky J.L., McConnell D., Sowers M.F., Weiss G. Correlates of circulating androgens in mid-life women: the study of women's health across the nation. J. Clin. Endocrinol. Metab. 2005, 90:4836-4845.
26. Schuring A.N., Schulte N., Sonntag B., Kiesel L. Androgens and insulin-two key players in polycystic ovary syndrome. Recent concepts in the pathophysiology and genetics of polycystic ovary syndrome. Gynakol. Geburtshilfliche Rundsch. 2008, 48:9-15.
27. Stener-Victorin E., Holm G., Labrie F., Nilsson L., Janson P.O., Ohlsson C. Are there any sensitive and specific sex steroid markers for polycystic ovary syndrome?. J. Clin. Endocrinol. Metab. 2010, 95:810-819.
28. Svanborg P., Asberg M. A new self-rating scale for depression and anxiety states based on the Comprehensive Psychopathological Rating Scale. Acta Psychiatr. Scand. 1994, 89:21-28.
29. Sverrisdottir Y.B., Mogren T., Kataoka J., Janson P.O., Stener-Victorin E. Is polycystic ovary syndrome associated with high sympathetic nerve activity and size at birth?. Am. J. Physiol. Endocrinol. Metab. 2008, 294:E576-E581.
30. Taylor V.H., Macqueen G.M. The role of adipokines in understanding the associations between obesity and depression. J. Obes. 2010, 2010.
31. Teede H., Deeks A., Moran L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med. 2010, 8:41.
32. The Rotterdam ESHRE/ASRM sponsored PCOS Consensus Workshop Group Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum. Reprod. 2004, 19:41-47.
33. Thomson R.L., Buckley J.D., Lim S.S., Noakes M., Clifton P.M., Norman R.J., Brinkworth G.D. Lifestyle management improves quality of life and depression in overweight and obese women with polycystic ovary syndrome. Fertil. Steril. 2010, 94:1812-1816.
34. Tschoner A., Engl J., Laimer M., Kaser S., Rettenbacher M., Fleischhacker W.W., Patsch J.R., Ebenbichler C.F. Metabolic side effects of antipsychotic medication. Int. J. Clin. Pract. 2007, 61:1356-1370.
35. Tyrer P., Owen R.T., Cicchetti D.V. The brief scale for anxiety: a subdivision of the comprehensive psychopathological rating scale. J. Neurol. Neurosurg. Psychiatry 1984, 47:970-975.
36. Vermeulen A., Verdonck L., Kaufman J.M. A critical evaluation of simple methods for the estimation of free testosterone in serum. J. Clin. Endocrinol. Metab. 1999, 84:3666-3672.
37. Weber B., Lewicka S., Deuschle M., Colla M., Heuser I. Testosterone, androstenedione and dihydrotestosterone concentrations are elevated in female patients with major depression. Psychoneuroendocrinology 2000, 25:765-771.
38. Weiner C.L., Primeau M., Ehrmann D.A. Androgens and mood dysfunction in women: comparison of women with polycystic ovarian syndrome to healthy controls. Psychosom. Med. 2004, 66:356-362.
39. Zimmerman M., Posternak M.A., Chelminski I. Derivation of a definition of remission on the Montgomery-Asberg depression rating scale corresponding to the definition of remission on the Hamilton rating scale for depression. J. Psychiatr. Res. 2004, 38:577-582.